



**Complete if Known**

<b>Application Number</b>	Wolfgang Doering et al.	10595067
<b>Filing Date</b>	January 27, 2006	
<b>First Named Inventor</b>	WOLFGANG DÖRING ET AL.	
<b>Group Art Unit</b>	Unknown	
<b>Examiner Name</b>	Unknown	
<b>Attorney Docket Number</b>	WAS 0757 PUSA	

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Examiner Signature	/Mark Berch/ (04/25/2008)	Date Considered	
-----------------------	---------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Substitute for Form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/595,067
				<b>Filing Date</b>	January 27, 2006
				<b>First Named Inventor</b>	WOLFGANG DÖRING ET AL.
				<b>Group Art Unit</b>	Unknown
				<b>Examiner Name</b>	Unknown
<b>Sheet</b>	2	of	2	<b>Attorney Docket Number</b>	WAS 0757 PUSA
<b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials</b>	<b>Cite No.<sup>1</sup></b>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			<b>T<sup>2</sup></b>
		Kim et al., "1,3-Dioxolanylurine Nucleosides (2R,4R) and (2R,4S) with Selective Anti-HIV-1 Activity in Human Lymphocytes," J. MED. CHEM., Vol. 36, 1993, pp. 30-37			
		Evans et al., "Divergent Asymmetric Syntheses of Dioxolane Nucleoside Analogues," TETRAHEDRON: ASYMMETRY, Vol. 4, No. 11, 1993, pp. 2319-2322			
		Kim et al., "L-β-(2S,4S)- and L-α-(2S,4R)-Dioxolanyl Nucleosides as Potential Anti-HIV Agents: Asymmetric Synthesis and Structure-Activity Relationships," JOURNAL OF MEDICINAL CHEMISTRY, Vol. 36, No. 5, March 1993, pp. 519-528			
		Vobrüggen et al., "On the Mechanism of Nucleoside Synthesis," CHEM. BER. 114, 1981, pp. 1256-1268			
		March et al., "Advanced Organic Chemistry," Wiley & Sons, Inc., 3 <sup>rd</sup> Edition, p. 179 and pp. 310-317 1985			
		Greene et al., "Protection for the Hydroxyl Group Including 1,2- and 1,3-Diols," PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, Inc., 2 <sup>nd</sup> Edition, pp. 10-117 1991			
		"Protection for the Amino Group," PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, Inc., 2 <sup>nd</sup> Edition, pp. 309-385 (Greene et al., 1991)			

<b>Examiner Signature</b>	/Mark Berch/ (04/25/2008)	<b>Date Considered</b>	
-------------------------------	---------------------------	----------------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. \*Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/